-
Dr. Sigurd Berven to Highlight NOCISCAN Capabilities, Combining MR Spectroscopy and Augmented Intelligence (AI)
-
NOCISCAN as New Gold Standard in Identifying a Source of Discogenic Pain
BROOMFIELD, Colo., Jan. 31, 2025 (GLOBE NEWSWIRE) — Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its participation in the Selby Spine Conference. Renowned spine specialist, Dr. Sigurd Berven, will present Aclarion’s flagship platform, NOCISCAN, highlighting its innovative, evidence-supported capabilities.
“Aclarion is pleased to have NOCISCAN featured at the Shelby Spine Conference,” said Ryan Bond, Chief Strategy Officer. “We are honored to have renowned physicians like Dr. Berven illustrate how utilizing NOCISCAN can help physicians identify what they can’t ‘see’ with traditional imaging so they can personalize treatment for patients with chronic low back pain.”
Dr. Berven’s presentation, titled “MR Spectroscopy, Augmented Intelligence, and Low Back Pain – A New Gold Standard,” will delve into how NOCISCAN empowers physicians to noninvasively identify biomarkers that are invisible on traditional MRI scans. This breakthrough enables tailored, data-driven treatment plans for chronic low back pain patients.
Details of the Presentation:
- Date: Friday, January 31, 2025
- Time: 5:55 PM
- Location: Selby Spine Conference, Deer Valley, UT
NOCISCAN is revolutionizing spine surgery and chronic pain management by combining cutting-edge MR Spectroscopy with augmented intelligence, setting a new standard for noninvasive diagnostics.
Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s NOCISCAN solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. NOCISCAN objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, NOCISCAN provides critical insights into the location of a patient’s low back pain.
For a copy of the NOCISCAN presentation, please email: [email protected]
To find a NOCISCAN center, view our site map here.
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with NOCISCAN, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, NOCISCAN receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, NOCISCAN provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
[email protected]
Media Contact:
Jennie Kim
SPRIG Consulting
[email protected]
